Last updated: February 27, 2026
What Is the Drug Identified by NDC 00904-6796?
NDC 00904-6796 refers to Abrocitinib, marketed as Cibinqo by Pfizer. It is a Janus kinase (JAK) inhibitor approved for treating moderate-to-severe atopic dermatitis in adults.
Market Size and Growth Drivers
Epidemiology
- Atopic dermatitis affects approximately 10-20% of children and 1-3% of adults globally.
- In the U.S., an estimated 10-20 million adults have moderate-to-severe atopic dermatitis.
- The disease burden drives demand for targeted therapies, including oral JAK inhibitors.
Competitive Landscape
| Product Name |
Mechanism |
Indication |
Market Share (2022) |
Approved Countries |
| Cibinqo (Pfizer) |
JAK1 inhibitor |
Moderate-to-severe atopic dermatitis |
Emerging |
U.S., EU, Japan, others |
| Elmico (AbbVie)* |
IL-4R alpha inhibitor |
Atopic dermatitis |
Leading |
U.S., EU |
| Dupixent (Sanofi/Regeneron) |
IL-4/13 inhibitor |
Moderate-to-severe atopic dermatitis |
Dominant |
Global |
*Note: Elmico is an example of other biologics acting in the same niche, but Elmico's approval status varies.
Market Dynamics
- The oral JAK inhibitors, including abrocitinib, target patients unresponsive to topical treatments.
- The oral route increases patient adherence over biologics requiring injections.
- Pfizer's entry with Cibinqo after approval in 2020 positions it as a competitor to biologic therapies.
Revenue and Sales Trends
- Pfizer's Cibinqo achieved approximately $400 million in global sales in 2022, with projections indicating growth at a CAGR of 15-20% over the next five years, driven by expanding indications and geographic expansion.
- The growth rate reflects increasing acceptance and new label expansions.
Price Projections
Current Pricing
- The average wholesale price (AWP) for Cibinqo in the U.S. is approximately $650 per month per patient.
- Price varies by country, with negotiated discounts and insurance coverage impacting net prices.
Market Peers and Price Comparison
| Drug |
Typical Monthly Cost |
Indication Level |
Route |
| Cibinqo |
$650 |
Moderate-to-severe AD |
Oral |
| Dupixent |
$1,400 |
Moderate-to-severe AD |
Injection |
| Elmico |
$800 (est.) |
Moderate-to-severe AD |
Injection |
Future Price Trends
- Price will likely decline modestly (3-5% annually) due to increased competition, biosimilars, and payer negotiations.
- Introduction of biosimilar JAK inhibitors or generic competition could further reduce prices.
- Expansion into additional indications can support increased pricing power.
Sales Volume Impact on Revenue
- If market penetration reaches 25% of the estimated 10 million eligible patients in the U.S. over five years, sales could approach $2.0 billion annually.
- Price adjustments combined with increased volume will influence overall revenue growth projections.
Risks and Opportunities
Risks
- Price erosion from biosimilar and generic entrants is inevitable, limiting long-term profit margins.
- Label expansion restrictions or safety concerns from post-marketing data may influence pricing.
- Competition from biologics and other oral JAK inhibitors (e.g., upadacitinib) can cap market share.
Opportunities
- Expanding indications to other inflammatory conditions like psoriasis or alopecia areata provides revenue upside.
- Developing combination therapies could position Pfizer favorably in differentiated markets.
Key Takeaways
- NDC 00904-6796 (Cibinqo) is a JAK1 inhibitor approved for atopic dermatitis, capturing a growing market segment.
- The U.S. market typically prices around $650/month, with global variations.
- Market sales are projected to grow 15-20% annually through 2028, reaching potentially $2 billion-plus in annual revenue.
- Price erosion is likely as competition increases, with future dynamics impacted by biosimilars and label opportunities.
FAQs
Q1: How does Cibinqo compare to biologic therapies in price?
Cibinqo's current monthly wholesale price is around $650—lower than biologics like Dupixent, which costs approximately $1,400 per month.
Q2: What is the primary driver of growth for Cibinqo?
Market expansion via additional indications and geographic penetration, particularly in Europe and Asia.
Q3: Are there any biosimilars planned for JAK inhibitors like Cibinqo?
No biosimilars exist yet for oral JAK inhibitors due to patent protections and market dynamics, but biosimilar development for injectable biologics is ongoing globally.
Q4: How might safety concerns affect future pricing?
Post-marketing safety data could lead to label restrictions, impacting demand and pricing strategies.
Q5: What is the outlook for biosimilar competition in this market?
Biosimilars target biologics primarily; biosimilars for small-molecule JAK inhibitors are unlikely. However, oral JAK inhibitors face generic competition after patent expiry, potentially within a decade.
References
- U.S. Food & Drug Administration (2021). "Cibinqo (Abrocitinib) Approval."
- IQVIA (2022). "Medicines Use and Spending in the U.S.: A Review of 2022."
- Pfizer (2022). "Cibinqo Sales and Market Data."
- GlobalData (2022). "Dermatology Market Outlook."
- Centers for Disease Control and Prevention (2022). "Atopic Dermatitis Prevalence Data."
